Novartis: Oddo upgrades rating; ups target price
(CercleFinance.com) - Oddo has raised its target price on the Novartis stock to 88 Swiss francs (against 85 Swiss francs), upgrading its corresponding rating to Buy (vs.
Neutral).
Novartis yesterday announced the sale of its 36.5% stake in the Consumer HealthCare (CHC) joint venture to its partner GSK for a total amount of 13 billion dollars.
Novartis' new CEO has a Ph.D, and was formerly Novartis' Head of Drug Development and CMO. He is therefore likely to strengthen Novartis' Pharma business with acquisitions (biotechs?). The timing of the OTC transaction makes us think that we could see a deal from the second half of 2018, Oddo says.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Neutral).
Novartis yesterday announced the sale of its 36.5% stake in the Consumer HealthCare (CHC) joint venture to its partner GSK for a total amount of 13 billion dollars.
Novartis' new CEO has a Ph.D, and was formerly Novartis' Head of Drug Development and CMO. He is therefore likely to strengthen Novartis' Pharma business with acquisitions (biotechs?). The timing of the OTC transaction makes us think that we could see a deal from the second half of 2018, Oddo says.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.